Download presentation
Presentation is loading. Please wait.
Published byFanny Hermawan Modified over 6 years ago
1
Treatment of Locally Advanced Pancreatic Cancer
2
Resectability of Pancreatic Adenocarcinoma at Diagnosis
3
Overview of Discussion
4
Phase 3 PRODIGE 24/CCTG PA.6 Trial Study Design
5
PRODIGE 24/CCTG PA.6 Trial Efficacy
6
PRODIGE 24/CCTG PA.6 Trial Disease-Free Survival
7
PRODIGE 24/CCTG PA.6 Trial Overall Survival
8
Phase 2 LAPACT Trial Study Design
9
LAPACT Trial Efficacy
10
Strengths and Limitations of the LAPACT Trial
11
Phase 3 LAP07 Trial Study Design
12
LAP07 Trial Efficacy in Gemcitabine-Only Arm
13
Phase 2 SCALOP Trial Study Design
14
SCALOP Trial Efficacy (Long-Term Follow-Up)
15
LAPACT Trial Best Response to Induction
16
LAPACT Trial Best Change From Baseline in Target Lesions
17
LAPACT Trial PFS and OS Kaplan-Meier Curves
18
LAPACT Trial Quality of Life During Induction
19
Summary of Clinical Trials Assessing Induction or Neoadjuvant Chemotherapy in LAPC
20
Phase 3 PREOPANC-1 Trial Study Design
21
PREOPANC-1 Trial Efficacy
22
PREOPANC-1 Trial Overall Survival in Intention to Treat Population
23
PREOPANC-1 Trial Overall Survival After R0/R1 Resection
24
PREOPANC-1 Trial Safety
25
LAPACT Trial Safety
26
PRODIGE Trial Key Takeaway
27
Emerging Role for Stereotactic Body Radiation Therapy in LAPC
28
New Standard of Care: Genetic Profiling in Pancreatic Cancer
29
ASCO® Guidelines for Potentially Curable Localized Pancreatic Adenocarcinoma
30
PRODIGE 24/CCTG PA.6 Trial Planned Dose Reduction of Irinotecan
31
PRODIGE 24/CCTG PA.6 Trial Adverse Events
32
LAPACT Trial–Toxicity Further Analysis
33
LAPACT Trial EORTC Quality-of-Life Scores (QLQ-C30)
34
Patient’s Overall Global Health With nab-Paclitaxel and Gemcitabine
35
Take-Home Points
36
Abbreviations
37
Abbreviations (cont)
38
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.